COVID-19 vaccine effectiveness against severe disease from the Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022-Reference-Cited by-同舟云学术

COVID-19 vaccine effectiveness against severe disease from the Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022

Published:2022-04-18 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Björk Jonas^ORCID,Bonander Carl^ORCID,Moghaddassi Mahnaz^ORCID,Rasmussen Magnus^ORCID,Malmqvist Ulf,Inghammar Malin^ORCID,Kahn Fredrik^ORCID

Abstract

AbstractWe compared vaccine effectiveness (VE) against severe COVID-19 during calendar periods from December 2021 to March 2022 when Omicron BA.1 and BA.2, respectively, were the dominating virus variants in Scania county, Sweden. We used continuous density case-control sampling matched for sex and age, and with further adjustment for differences in comorbidities and prior infection. VE remained relatively stable after the transition from BA.1 to BA.2 among people with at least three doses but decreased markedly among those with only two doses. Protection from prior infection was also lower after the transition to BA.2. These findings suggest that booster vaccination is needed to maintain sufficient protection against severe COVID-19.

Publisher

Cold Spring Harbor Laboratory

Reference10 articles.

1. Lyngse FP , Kirkeby CT , Denwood M , Christiansen LE , Mølbak K , Møller CH , et al. Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish Households. medRxiv. 2022.

2. Kirsebom FCM , Andrews N , Stowe J , Toffa S , Sachdeva R , Gallagher E , et al. COVID-19 Vaccine Effectiveness against the Omicron BA.2 variant in England. medRxiv. 2022.

3. Altarawneh HN , Chemaitelly H , Ayoub HH , Tang P , Hasan MR , Yassine HM , et al. Effect of prior infection, vaccination, and hybrid immunity against symptomatic BA.1 and BA.2 Omicron infections and severe COVID-19 in Qatar. medRxiv. 2022.

4. Björk J , Inghammar M , Moghaddassi M , Rasmussen M , Malmqvist U , Kahn F. High level of protection against COVID-19 after two doses of BNT162b2 vaccine in the working age population -first results from a cohort study in Southern Sweden. Infectious diseases (London, England). 2021:1–6.

5. Kahn F , Bonander C , Moghaddassi M , Rasmussen M , Malmqvist U , Inghammar M , et al. Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities - surveillance results from southern Sweden, July 2021 to January 2022. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2022;27(9).